ZA200610546B - FGFR binding peptides - Google Patents

FGFR binding peptides

Info

Publication number
ZA200610546B
ZA200610546B ZA200610546A ZA200610546A ZA200610546B ZA 200610546 B ZA200610546 B ZA 200610546B ZA 200610546 A ZA200610546 A ZA 200610546A ZA 200610546 A ZA200610546 A ZA 200610546A ZA 200610546 B ZA200610546 B ZA 200610546B
Authority
ZA
South Africa
Prior art keywords
compounds
ncam
fgfr
peptide sequences
peptide
Prior art date
Application number
ZA200610546A
Other languages
English (en)
Inventor
Bock Elisabeth
Berezin Vladimir
Original Assignee
Dk Fruebjergvej 3 Dk 2100 Cope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dk Fruebjergvej 3 Dk 2100 Cope filed Critical Dk Fruebjergvej 3 Dk 2100 Cope
Publication of ZA200610546B publication Critical patent/ZA200610546B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200610546A 2004-06-18 2006-12-15 FGFR binding peptides ZA200610546B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400963 2004-06-18

Publications (1)

Publication Number Publication Date
ZA200610546B true ZA200610546B (en) 2008-06-25

Family

ID=35510321

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610546A ZA200610546B (en) 2004-06-18 2006-12-15 FGFR binding peptides

Country Status (11)

Country Link
US (1) US20090074774A1 (de)
EP (1) EP1765861B1 (de)
JP (1) JP2008504236A (de)
CN (1) CN101027320A (de)
AT (1) ATE545655T1 (de)
AU (1) AU2005254613A1 (de)
BR (1) BRPI0512254A (de)
CA (1) CA2570267A1 (de)
MX (1) MXPA06014804A (de)
WO (1) WO2005123759A2 (de)
ZA (1) ZA200610546B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678200B1 (de) * 2003-09-30 2012-05-02 Enkam Pharmaceuticals A/S Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität
WO2007093177A2 (en) * 2006-02-14 2007-08-23 Vladimir Berezin Metallothionein-derived peptide fragments
WO2007110079A2 (en) * 2006-03-29 2007-10-04 Enkam Pharmaceuticals A/S Targeted delivery of fgfr ligands into the brain
CN101619093B (zh) * 2009-05-26 2011-12-07 中国人民解放军第三军医大学野战外科研究所 具有促进成纤维细胞生长因子受体3活性的多肽及其筛选方法和应用
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2013184824A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
CN109867724B (zh) * 2019-04-19 2020-09-15 温州医科大学 一种fgfr抗体及其在脊髓损伤治疗中的用途
JPWO2024195709A1 (de) * 2023-03-17 2024-09-26
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020104122A1 (en) * 1994-06-17 2002-08-01 Kirin Beer Kabushiki Kaisha Methods for producing a plant with enhanced resistance to pathogenic fungi
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
ATE552273T1 (de) * 2001-08-17 2012-04-15 Enkam Pharmaceuticals As Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
KR20060129229A (ko) * 2003-11-21 2006-12-15 에이스 바이오사이언시즈 에이/에스 표면에 위치한 빈창자캄필로박터 폴리펩티드

Also Published As

Publication number Publication date
WO2005123759A2 (en) 2005-12-29
WO2005123759A3 (en) 2006-05-04
WO2005123759A8 (en) 2006-03-09
JP2008504236A (ja) 2008-02-14
MXPA06014804A (es) 2007-03-23
AU2005254613A1 (en) 2005-12-29
BRPI0512254A (pt) 2008-02-19
ATE545655T1 (de) 2012-03-15
EP1765861A2 (de) 2007-03-28
EP1765861B1 (de) 2012-02-15
CN101027320A (zh) 2007-08-29
CA2570267A1 (en) 2005-12-29
US20090074774A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
ZA200610546B (en) FGFR binding peptides
WO2007093177A3 (en) Metallothionein-derived peptide fragments
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
IL173532A0 (en) Compounds comprising lpa
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2007117657A3 (en) Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2007051477A3 (en) Neurotrophin-derived peptide sequences
DK170649B1 (da) Corticotropinderivater og fysiologisk acceptable salte deraf, deres fremstilling og lægemidler, der indeholder dem
WO2002074956A3 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
WO2007019860A3 (en) Gdnf derived peptides
Hanessian et al. Structure-based organic synthesis of unnatural aeruginosin hybrids as potent inhibitors of thrombin
WO2006110588A8 (en) Methods for treating mild cognitive impairment
WO2009068042A3 (en) Novel peptides derived from ncam (fgls)
WO2005025514A3 (en) Compounds that modulate neuronal growth and their uses
WO2008086524A3 (en) Alpha-1-antitrypsin variants and uses thereof
WO2007074456A3 (en) Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
WO2007071248A3 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
WO2007045243A3 (en) Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
WO2003020749A3 (en) Ncam binding compounds
WO2003097687A3 (en) Neuroprotective polypeptides and methods of use
DK1438329T3 (da) Biologisk aktive peptider og deres anvendelse til reparation af beskadigede nerver
WO2004041843A3 (en) Hop - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification
WO2005121168A3 (en) Heparin binding peptide
Janke et al. The arginine mimicking β-amino acid β3hPhe (3-H2N-CH2) as S1 ligand in cyclotheonamide-based β-tryptase inhibitors